renal general-medicine
CKD Staging (KDIGO 2012)
Stages chronic kidney disease (CKD) by GFR category (G1-G5) and albuminuria category (A1-A3) per KDIGO 2012 guidelines.
Score interpretation
Low risk CKD (G1-G2, A1)
→ Annual monitoring; manage cardiovascular risk factors; avoid nephrotoxins
Moderate risk CKD
→ 6-monthly review; RAAS inhibitor if proteinuric; lifestyle intervention
High risk CKD (G3b-G4 or A3)
→ Nephrology referral; anaemia and bone disease management; dialysis planning
Very high risk / CKD G5
→ Nephrology; renal replacement therapy planning (HD, PD, transplant); conservative pathway if appropriate
Interpretation bands for the CKD Stage (KDIGO). Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Methotrexate (Dermatology — Psoriasis) · Disease-Modifying Antirheumatic / Immunosuppressant
- Omalizumab (Dermatology — Chronic Urticaria) · Anti-IgE Monoclonal Antibody
- Cetuximab · Anti-EGFR Monoclonal Antibody — Head and Neck Cancer
- Acetazolamide (Ménière's Disease) · Carbonic Anhydrase Inhibitor (Diuretic)
- Zinc acetate · Zinc salt (Wilson's disease)
- Fentanyl Transdermal Patch (Elderly Chronic Pain) · Opioid Analgesic — Transdermal Patch
Pathways
- Hyperkalaemia Management · UK Kidney Association Guidelines 2020; NICE CKD Guidelines
- Rhabdomyolysis · Renal Association 2018; UpToDate 2024
- Hypocalcaemia (Adult) · Society for Endocrinology
- SIADH (Endocrine Perspective) · European Hyponatraemia Guidelines 2014
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Acute Kidney Injury (AKI) · KDIGO 2012 / NICE AKI 2019
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.